Momesonex (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid receptor agonist. After binding to intracellular receptors in nasal mucosal cells, it modulates gene expression to suppress the release of inflammatory mediators, decreasing swelling, mucus production, and immune cell infiltration in the nasal passages.

The exact dosing regimen for Momesonex is determined by the prescribing healthcare professional. Typically, the label recommends one or two sprays per nostril once daily, but the prescriber may adjust the dose based on the patient’s age, severity of symptoms, and clinical response.

The safety of mometasone furoate nasal spray in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Momesonex.

To order Momesonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Momesonex (mometasone furoate) is a high‑potency nasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in controlling allergic rhinitis, while its once‑daily dosing may improve adherence relative to some alternatives.

Momesonex should be stored at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture and direct sunlight. Keep the device upright and do not expose it to extreme temperatures, which could affect spray performance.

Before first use, prime the spray by pressing the actuator several times until a fine mist appears. Tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril with a finger, and spray the prescribed number of sprays while breathing in gently. Repeat in the other nostril if directed.

Serious adverse events, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes (including cataract formation), adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek medical attention if any of these occur.

Momesonex is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery, or those who are already using another nasal corticosteroid without medical supervision.